Engineered monoclonal antibodies have been developed to target specific regions of a TAT-C1aB fusion peptide with high precision. Two antibodies recognize the TAT segment while three target the C1aB segment, with a pair biotinylated to boost detection sensitivity. This configuration is employed in a sandwich ELISA format that necessitates one antibody binding each segment, ensuring that only the intact peptide is detected in biological fluids. The method supports pharmacokinetic studies by tracking the distribution, metabolism, and concentration of the neuroprotective peptide in various biological systems.